<DOC>
	<DOCNO>NCT02405910</DOCNO>
	<brief_summary>Phase II study determine progression free survival ( PFS ) nab-paclitaxel administer combination gemcitabine , two different dose combination first line therapy patient unresectable stage IIIB/stage IV non-squamous non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>Ph2 Nab-paclitaxel With Gemcitabine Determine Efficacy Advanced Non-squamous NSCLC .</brief_title>
	<detailed_description>This study design determine progression free survival ( PFS ) nab-paclitaxel administer combination gemcitabine two different dose combination patient unresectable stage IIIB/stage IV non-squamous non-small cell lung cancer ( NSCLC ) . Two dose strategy nab-paclitaxel plus gemcitabine combination compare efficacy tolerability . One arm combine agent current Food Drug Administration ( FDA ) approve dos indication non-small cell lung cancer ( NSCLC ) . This arm utilize gemcitabine 1250 mg/m2 IV day 1 day 8 ( FDA approve dose combination cisplatin ) combine nab-paclitaxel 100 mg/m2 IV day 1 , 8 15 every 21 day ( FDA approve dose combination carboplatin ) . The second arm utilize drug dose approved FDA combine one another metastatic pancreatic adenocarcinoma . This arm consist gemcitabine 1000 mg/m2 IV day 1 , 8 15 combine nab-paclitaxel 125 mg/m2 IV day 1 , 8 15 every 28 day . Patients randomize equally two treatment arm . Primary objective ass progression-free survival ( PFS ) . Toxicity assessment , response overall survival secondary endpoint . Statistical power base comparison historical control within treatment arm . In particular , sample size 23 patient arm 84 % power differentiate 3-month PFS 30 % ( null hypothesis ) versus 60 % ( alternative ) base 2-sided test significance level 0.05 . There lead-in phase trial treatment arm cohort size 3 maximum 6 patient .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Patients histologically prove newly diagnose stage IV stage IIIB nonsquamous Nonsmall Cell Lung Cancer ( NSCLC ) Recurrent advance NSCLC allow never receive chemotherapy metastatic disease . Prior adjuvant chemotherapy allow , recurrence occur ≥ 6 month last treatment Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 Washout period 4 week chemo/radiation/experimental agent Resolution toxicity &lt; grade 2 prior start treatment ( exclude alopecia ) Patients must &lt; Grade 2 preexist peripheral neuropathy ( per CTCAE ) Adequate hepatic , renal , bone marrow function Women childbearing potential sexually active male must use effective contraception method treatment three month complete treatment Negative serum urine βhCG pregnancy test screening patient childbearing potential Patient New York Heart Association class III IV heart failure Women child bear potential ( WOCBP ) currently pregnant breastfeed Coexisting malignancy malignancy diagnose within last 3 year exception basal cell carcinoma Previous anaphylactic severe allergic reaction paclitaxel and/or docetaxel exclude Grade ≥2 peripheral neuropathy baseline assessment cause Symptomatic brain metastasis exclude . Treated Brain metastasis allow neurologically stable . Patients adenocarcinoma activate EGFR mutation ( exon 19 deletion / insertion , exon 21 point mutation ) EML4ALK translocation exclude unless ineligible epidermal growth factor receptor ( EGFR ) ALK target agent . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>advanced</keyword>
	<keyword>non-squamous</keyword>
	<keyword>first line therapy</keyword>
</DOC>